Younger kidney cancer patients on VEGF inhibitors at elevated risk for hypertension
Hypertension during treatment is common among adolescents and young adults (AYAs) being treated with vascular endothelial growth factor (VEGF) inhibitors for renal cancer, according to a study published online July 5 in the Journal of the National Comprehensive Cancer Network. Wendy J. Bottinor, M.D., from Virginia Commonwealth University in Richmond, and colleagues assessed the incidence and predictors of left ventricular […]
Continue reading »